Packed Red Blood Cell Transfusion During Cardiac Arrest

Last updated: April 30, 2025
Sponsor: NYU Langone Health
Overall Status: Active - Recruiting

Phase

1

Condition

Heart Failure

Circulation Disorders

Heart Attack (Myocardial Infarction)

Treatment

Saline

Packed Red Blood Cells (1 unit)

Packed Red Blood Cells (2 units)

Clinical Study ID

NCT06462027
18-01273
  • Ages 18-85
  • All Genders

Study Summary

The purpose of this pilot interventional study is to collect preliminary data on administering packed red blood cell (PRBC) during cardiac arrest (CA). The primary objective is to assess the feasibility of PRBC transfusion during cardiac CA to help optimize the methods required to augment cerebral and other vital organ oxygen delivery during cardiopulmonary resuscitation (CPR). The secondary objectives are to assess the effect of PRBC transfusion during prolonged cardiac arrests on cerebral oxygenation, end tidal carbon dioxide (ETCO2), return of spontaneous circulation (ROSC), survival to discharge, biomarkers of neural injury and inflammation, and neurological outcomes at hospital discharge, 30 days post-CA, and 90 days post-CA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patients, age ≥18 and <85 years

  • Experience prolonged, non-trauma-related in-hospital cardiac arrest, defined bycessation of heartbeat and respiration requiring CPR for at least 10 minutes

Exclusion

Exclusion Criteria:

  • Age <18 years old

  • Age > 85 years old

  • Patients with DNR/DNI orders (Do Not Resuscitate/Do Not Intubate)

  • Patients admitted to the hospital with a cardiac arrest arising from trauma

  • Patients who achieve return of spontaneous circulation within 10 minutes of CPR

  • Inability to start study product administration within 20 minutes of cardiac arrestonset

  • Prisoners

  • Women who are known to be pregnant

  • Patients with a history of RBC antibodies or positive antibody screen prior toenrollment in the study, unless previously cross-matched units are available fortransfusion.

  • Patients with ultrasound evidence of right ventricular dilatation at time of CA

  • Patients with known prior objection to receipt of blood products.

  • Patients for whom administration of additional fluid volume is contraindicated (asdetermined by physician responsible for care)

  • Physician objection based on concern that intervention would interfere with patientcare plan

Study Design

Total Participants: 30
Treatment Group(s): 3
Primary Treatment: Saline
Phase: 1
Study Start date:
March 25, 2025
Estimated Completion Date:
April 01, 2026

Connect with a study center

  • NYU Langone Health

    New York, New York 10016
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.